Astellas Pharma Inc. (YPH.F)

8,75 -0,01 (-0,14%) Alla chiusura: 09:49PM CEST

Astellas Pharma Inc.

2-5-1, Nihonbashi-Honcho
Chuo-Ku
Tokyo 103-8411
Japan
81 3 3244 3000
https://www.astellas.com

Settore/i: Healthcare
Settore: Drug Manufacturers - General
Impiegati a tempo pieno: 

Figure dirigenziali chiave

Nome	Titolo	Retribuzione	Esercitate	Anno di nascita
Mr. Naoki Okamura BSc	President, CEO & Director	867,69k	N/D	1962
Mr. Atsushi Kitamura	Chief Financial Officer	N/D	N/D	N/D
Nobue Yasuda	General Manager of Finance & Accounting Department	N/D	N/D	N/D
Mr. Yoshitsugu Shitaka Ph.D.	Chief Scientific Officer & Senior Managing Executive Officer	N/D	N/D	N/D
Ms. Catherine B. Levitt	General Counsel	N/D	N/D	N/D
Mr. Katsuyoshi Sugita	Chief People Officer, Chief Ethics & Compliance Officer, EVP of HR and Representative Director	N/D	N/D	1967
Mr. Stig Ogata	Vice President of Corporate Communications	N/D	N/D	N/D
Ms. Collette Taylor	Senior Vice President of Human Resources	N/D	N/D	1963
Ms. Tatjana Dragovic	Senior VP and Head of Ethics & Compliance	N/D	N/D	N/D
Mr. Nobuaki Tanaka	President of Japan Commercial & Senior Corporate Executive	N/D	N/D	N/D

Gli importi risalgono al giorno 31 dicembre 2023 e i valori di compensazione riguardano l'anno fiscale che si chiude a tale data. La retribuzione include salari, bonus ecc. "Esercitate" è il valore delle opzioni esercitate durante l'anno fiscale. Valuta in EUR.

Descrizione

Astellas Pharma Inc. manufactures, markets, and imports and exports pharmaceuticals in Japan and internationally. The company provides XTANDI, a treatment for prostate cancer; XOSPATA, a treatment for patients who have relapsed or refractory acute myeloid leukemia with a FLT3 mutation; and PADCEV, a treatment for patients with metastatic urothelial cancer. It also offers Evrenzo, a treatment for anemia associated with chronic kidney disease; Betanis/Myrabetriq/BETMIGA, a treatment for overactive bladder; and Prograf and Advagraf/Graceptor/ASTAGRAF XL immunosuppressants. Th company has a research collaboration with Vivtex Corporation to evaluate Vivtex's GI-ORIS screening and formulation platform technology to support the development of novel and oral versions of a therapeutic candidate provided by Astellas; and a partnership agreement with Roche Diabetes Care Japan Co., Ltd. to develop and commercialize integrated diabetes self-management solution. The company was founded in 1923 and is headquartered in Tokyo, Japan.

Governance aziendale

L'ISS Governance QualityScore di Astellas Pharma Inc. al 29 aprile 2024 è 2. I criteri di valutazione fondamentali sono revisione: 1; Consiglio di Amministrazione: 2; diritti degli azionisti: 6; retribuzione: 1.

Punteggi di corporate governance forniti da Institutional Shareholder Services (ISS). I punteggi indicano il rango decile relativo all’indice o alla regione. Un punteggio di decile pari a 1 indica un governance risk più basso, mentre un punteggio di 10 indica un governance risk più alto.